Trinity Biotech Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.50next fiscal year
Monitoring Framework
Key Performance Indicators
TrinScreen HIV Test Sales Volume Quarterly2MTarget: Fulfillment of over 2 million units in Q3 2026
Gross Profit Margin Quarterly3,540.0%Target: Substantial improvement through outsourced manufacturing model
Adjusted EBITDA Quarterly-1.1MTarget: Positive annualized run rate EBITDASO of $20 million
Watch Items
- Nasdaq Listing Compliance (Minimum Market Value of Publicly Held Shares & Minimum Bid Price)Trigger: Cure period deadline of August 18, 2026Action: Monitor share price and market value; execute capital structure adjustments or reverse stock splits if necessary to maintain listing.
- UniGold HIV Rapid Test Outsourced Manufacturing Scale-UpTrigger: Substantial completion expected during Q3 2026Action: Track transition milestones to ensure gross margin expansion and mitigate quarter-on-quarter revenue variability.
- CGM+ Biosensor Platform Development and Capex RequirementsTrigger: Required capex of $15 million to $25 million in 2026Action: Monitor clinical trial progress, regulatory filings, and capital allocation to support the flagship development pipeline.
Research as of 20 Jun 2026